Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Gearry

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Journal of Crohn'S & Colitis|February 26, 2013
Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-responseK Sutharshan, R B Gearry
Alimentary Pharmacology & Therapeutics|July 13, 2018
Editorial: ustekinumab and Crohn's disease-what can we learn from long-term extension studies?R B Gearry, C Daker
Digestive Diseases and Sciences|February 16, 2010
Rifaximin and Crohn's disease: a new solution to an old problem?A S Day, R B Gearry
Alimentary Pharmacology & Therapeutics|December 12, 2017
Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageingA J Willington, R B Gearry
Journal of Gastroenterology and Hepatology|September 27, 2017
Gastrointestinal: Hepatic abscess after botulinum toxin type-A therapy for achalasiaH Giles, A Ross, R B Gearry
Journal of Crohn'S & Colitis|June 12, 2012
S100A12 in EDTA plasma - a cautionary taleB Meijer, R B Gearry, A S Day
International Journal of Inflammation|July 20, 2012
The role of S100A12 as a systemic marker of inflammationB Meijer, R B Gearry, A S Day
Australasian Radiology|April 23, 2005
Spontaneous calcific cerebral embolusR B Gearry, J P Sharr, S F Avery
Alimentary Pharmacology & Therapeutics|April 19, 2017
Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?M J Lamba, V S Tharayil, R B Gearry
Alimentary Pharmacology & Therapeutics|June 17, 2017
Editorial: does disease extension lead to disease progression in proctitis?M J Lamba, V S Tharayil, R B Gearry
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Journal of Crohn'S & Colitis|February 26, 2013
Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-responseK Sutharshan, R B Gearry
Alimentary Pharmacology & Therapeutics|July 13, 2018
Editorial: ustekinumab and Crohn's disease-what can we learn from long-term extension studies?R B Gearry, C Daker
Digestive Diseases and Sciences|February 16, 2010
Rifaximin and Crohn's disease: a new solution to an old problem?A S Day, R B Gearry
Alimentary Pharmacology & Therapeutics|December 12, 2017
Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageingA J Willington, R B Gearry
Journal of Gastroenterology and Hepatology|September 27, 2017
Gastrointestinal: Hepatic abscess after botulinum toxin type-A therapy for achalasiaH Giles, A Ross, R B Gearry
Journal of Crohn'S & Colitis|June 12, 2012
S100A12 in EDTA plasma - a cautionary taleB Meijer, R B Gearry, A S Day
International Journal of Inflammation|July 20, 2012
The role of S100A12 as a systemic marker of inflammationB Meijer, R B Gearry, A S Day
Australasian Radiology|April 23, 2005
Spontaneous calcific cerebral embolusR B Gearry, J P Sharr, S F Avery
Alimentary Pharmacology & Therapeutics|April 19, 2017
Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?M J Lamba, V S Tharayil, R B Gearry
Alimentary Pharmacology & Therapeutics|June 17, 2017
Editorial: does disease extension lead to disease progression in proctitis?M J Lamba, V S Tharayil, R B Gearry
Pageof 4